SynthesisArchives of dermatological research2017
Prognostic factors for mortality in patients with bullous pemphigoid: a meta-analysis.
Synthesis in Archives of dermatological research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Prognostic factors for mortality in bullous pemphigoid: A systematic review and meta-analysis.PloS one · 2022Pooled it
- IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review.Archives of dermatological research · 2018Pooled it
- Bullous Pemphigoid Overlapping Psoriasis Vulgaris: A Rare Case Report and Literature Review.Clinics and practice · 2025Review
- Chronic disease associated with bullous pemphigoid risk: A systematic review and meta-analysis.JAAD international · 2024Article
- Risk of Serious Infections in Patients with Bullous Pemphigoid: A Population-based Cohort Study.Acta dermato-venereologica · 2023Article
- Targeting type 2 inflammation in bullous pemphigoid: current and emerging therapeutic approaches.Frontiers in medicine · 2023Review
- Clinical Effectiveness and Safety of Initial Combination Therapy with Corticosteroids and Rituximab in Bullous Pemphigoid: A Retrospective Cohort Study.American journal of clinical dermatology · 2022Article
- The efficacy of adding oral sodium cromoglycate to stable treatment for controlling bullous pemphigoid-related pruritus: A retrospective study.Frontiers in medicine · 2022Article
- Bullous pemphigoid: An immune disorder related to aging (Review).Experimental and therapeutic medicine · 2022Review
- A Review of Acquired Autoimmune Blistering Diseases in Inherited Epidermolysis Bullosa: Implications for the Future of Gene Therapy.Antibodies (Basel, Switzerland) · 2021Review
- A case report of dyshidrotic bullous pemphigoid developing after partial anterior circulation ischaemic stroke.Oxford medical case reports · 2021Article
- Emerging Biomarkers and Therapeutic Strategies for Refractory Bullous Pemphigoid.Frontiers in immunology · 2021Review
- Risk Factors for Mucosal Involvement in Bullous Pemphigoid and the Possible Mechanism: A Review.Frontiers in medicine · 2021Review
- Assessment of the Characteristics and Associated Factors of Infectious Complications in Bullous Pemphigoid.Frontiers in immunology · 2020Article
- The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid.Frontiers in immunology · 2019Review
- Microtubule-Actin Crosslinking Factor 1 and Plakins as Therapeutic Drug Targets.International journal of molecular sciences · 2018Review
- BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid.Frontiers in immunology · 2017Review
- Bullous pemphigoid.Anais brasileiros de dermatologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bullous pemphigoid (BP) is a chronic debilitating autoimmune blistering disease that frequently occurs in the elderly population. Previous studies have suggested a high morbidity and mortality associated with BP. However, relatively few studies have investigated prognostic factors of BP mortality, and they showed considerably various results. This meta-analysis aimed to quantitatively assess the association between several potential prognostic factors and risk of mortality in bullous pemphigoid. A comprehensive search was performed using Pubmed, Embase, and Cochrane Library. Cohort studies that assessed prognostic factors of BP mortality were included. Random-effects model was utilized to calculate the pooled hazard ratio (HR). Publication bias was evaluated qualitatively by constructing a funnel plot and quantitatively by conducting Egger's test. 14 studies were included comprising 2499 patients. Combined HRs suggested that advanced age (HR 1.63, 95% CI 1.34-1.97), presence of circulating antibodies (HR 1.77, 95% CI 1.20-2.62), concomitant dementia (HR 2.01, 95% CI 1.22-3.33), and concomitant stroke (HR 1.86, 95% CI 1.29-2.67) have an unfavorable impact on patient survival. Gender, disease extent, mucosal involvement, and indirect immunofluorescence result were not shown to be linked to mortality by our analysis. This study indicated that BP patients with older age, circulating antibodies, dementia, and stroke are at greater risk of mortality. Clinicians should be aware of this association and utilize this information in patient education and treatment process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.